<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple myeloma: Pathobiology</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple myeloma: Pathobiology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple myeloma: Pathobiology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dragan Jevremovic, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10 percent of all hematologic malignancies. It is an incurable disease and the cause of about 20 percent of deaths from hematologic malignancy and 2 percent of deaths from all cancers.</p><p>MM evolves from an asymptomatic premalignant stage of clonal plasma cell proliferation termed monoclonal gammopathy of undetermined significance (MGUS). MGUS is present in over 3 percent of the population above the age of 50 and progresses to MM or a related malignancy at a rate of 1 percent per year.</p><p>While MGUS is asymptomatic, MM is characterized by end-organ damage, which includes hypercalcemia, renal dysfunction, anemia, or lytic bone lesions. In some patients, an intermediate asymptomatic but more advanced premalignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically.</p><p>The pathobiology of MM will be reviewed here. The clinical and laboratory manifestations, diagnosis, and management of MGUS, SMM, and MM are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/95372.html" rel="external">"Smoldering multiple myeloma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CELL OF ORIGIN</span><span class="headingEndMark"> — </span>In general, MM arises from the malignant transformation of post-germinal center plasma cells [<a href="#rid1">1,2</a>]. The post-germinal ancestry of these cells is principally supported by the identification of somatic mutations in the variable region of the immunoglobulin (Ig) genes, which serve as a marker of germinal center transit. These cells also display ongoing somatic mutations, which reflect the pressure of antigen selection encountered by post-germinal center lymphocytes. By definition, class switching is demonstrated in IgG and IgA MM, but not in IgM MM. IgM MM is a very rare disease which appears to arise from a pre-germinal center plasma cell with translocations characterized by VDJ recombination-induced breakpoints [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/3977.html" rel="external">"Immunoglobulin genetics", section on 'Class-switching'</a>.)</p><p>The malignant plasma cells of MM have a low proliferative rate and have generally been unable to sustain tumor growth in vivo, suggesting that precursor cells are responsible for proliferation of the malignant cell population [<a href="#rid2">2,4-6</a>]. It has been proposed that these abnormal precursor B cells originate in the lymph nodes and migrate to the bone marrow, which provides a microenvironment conducive to terminal plasma cell differentiation [<a href="#rid7">7</a>]. This could explain the observation that the malignant plasma cells appear to be restricted to the microenvironment of the bone marrow, even though the disease is widely disseminated throughout the axial skeleton. (See <a class="local">'Bone marrow microenvironment'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">OVERVIEW OF PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathobiology of MM is a complex process leading to the replication of a malignant clone of plasma cell origin. While some steps in this pathway have been elucidated, many remain unknown. Virtually all MM cases are preceded by a premalignant plasma cell proliferative disorder known as monoclonal gammopathy of undetermined significance (MGUS) [<a href="#rid8">8</a>]. MGUS can be detected by standard assays in over 3 percent of the population above the age of 50, and it progresses to MM or a related malignancy at a rate of 1 percent per year. High sensitivity techniques such as mass spectrometry are able to detect MGUS in an even greater percentage of the population [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a> and  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p>The pathogenesis of MM can be conceptualized as two sequential processes  (<a class="graphic graphic_figure graphicRef78232" href="/z/d/graphic/78232.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Establishment of MGUS – While the inciting event is unknown, MGUS appears to develop as the result of cytogenetic abnormalities, many of which are thought to be the product of an abnormal plasma cell response to antigenic stimulation. The result is a plasma cell clone producing monoclonal immunoglobulin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progression from MGUS to MM – Further insults to the plasma cell clone, either through additional genetic abnormalities or changes in the bone marrow microenvironment, result in the progression of MGUS to MM.</p><p></p><p>In some patients, an intermediate asymptomatic but more advanced premalignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically. These patients may have been diagnosed in the midst of progressing from MGUS to MM, or they may represent biologic MGUS with a higher baseline clonal plasma cell burden. (See  <a class="medical medical_review" href="/z/d/html/95372.html" rel="external">"Smoldering multiple myeloma"</a>.) </p><p>Once the clonal plasma cell population is created and progresses to MM, patients develop symptoms (eg, hypercalcemia, lytic bone lesions, renal dysfunction, and anemia) related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">ESTABLISHMENT OF MGUS</span><span class="headingEndMark"> — </span>The first step in the pathway to the development of MM is the establishment of the premalignant plasma cell proliferative disorder known as monoclonal gammopathy of undetermined significance (MGUS). Patient-related and environmental risk factors for MGUS have been proposed, but the exact cause of MGUS development remains elusive.</p><p>Similar patterns of certain cytogenetic abnormalities can be found in the clonal plasma cells of MGUS and MM. These cytogenetic abnormalities are thought to lead to the creation of a plasma cell clone. (see <a class="local">'Cytogenetic abnormalities'</a> below)</p><p>While the event leading to these genetic changes likely varies, the most likely process is abnormal plasma cell response to antigenic stimulation. (See <a class="local">'Abnormal response to antigenic stimulation'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Epidemiologic data suggest a genetic predisposition as well as other potential risk factors including older age, immunosuppression, and environmental exposures [<a href="#rid10">10-14</a>]. Hormonal factors may play a role, since women have lower age-specific prevalence rates when compared with men.</p><p>A genetic predisposition is predominantly supported by the findings that the incidence of MGUS varies by ethnicity and that a small, but unknown, fraction of cases is familial. Such cases may be due to either shared genes or environmental factors. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Epidemiology'</a>.)</p><p>Exposure to radiation, benzene, and other organic solvents, herbicides, and insecticides may also play a role. However, the number of cases reported for each of these risk factors is small [<a href="#rid10">10-15</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Cytogenetic abnormalities</span><span class="headingEndMark"> — </span>Primary cytogenetic abnormalities appear to play a major role in the development of MGUS. Most, if not all, cases of MGUS and MM have chromosomal abnormalities that can be detected by fluorescence in situ hybridization (FISH), multicolor spectral karyotyping, comparative genomic hybridization, or gene expression profiling [<a href="#rid16">16-20</a>]. The percentage of cases demonstrating each abnormality varies by the detection method used and disease stage.</p><p>Most cases of MGUS appear to be initiated in conjunction with either translocation events involving the immunoglobulin heavy chain (IgH) locus (approximately 40 percent) or genetic instability manifested by trisomies (approximately 40 percent) or both translocations and trisomies (approximately 10 percent) [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Immunoglobulin heavy chain translocations</span><span class="headingEndMark"> — </span>The initial immune response (primary immune response) results in formation of IgM antibodies targeting the offending antigen. When exposed to the same antigen again, there may be a "class switch" that occurs wherein the genes coding for the variable portion of the IgH switch from the gene coding for the constant region of IgM to move next to the gene coding for the constant region of IgG (or IgA). As a result of this "switch recombination" or "class switching," the antibody made by the plasma cell changes from IgM type to IgG or IgA (secondary immune response). (See  <a class="medical medical_review" href="/z/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>.)</p><p>Approximately one-half of MGUS cases are likely caused by translocation events (errors) that occur at the time of immunoglobulin switch recombination. These translocations affect the IgH locus on chromosome 14q32, and result in the juxtaposition of an oncogene next to the IgH locus. This results in the aberrant expression of the affected oncogene and is thought to be a critical step in the development of MGUS. Cases that include these rearrangements are referred to as "IgH translocated MGUS" or "non-hyperdiploid MGUS." The most common partner chromosome loci and genes dysregulated in these translocations are  (<a class="graphic graphic_table graphicRef52114" href="/z/d/graphic/52114.html" rel="external">table 1</a>) [<a href="#rid23">23-26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>11q13 – cyclin D1 (<em>CCND1</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>6p21 – cyclin D3 (<em>CCND3</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>4p16.3 – multiple myeloma set domain (<em>MMSET</em>/<em>WHSC1</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>16q23 – musculoaponeurotic fibrosarcoma (<em>C-MAF</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>20q11 – musculoaponeurotic fibrosarcoma oncology family, protein B (<em>MAFB</em>)</p><p></p><p>The juxtaposition of these oncogenes next to the IgH locus results in overexpression of the oncogene induced by the active promoter region of the IgH genes. The products of this translocation then act as transcription factors, growth factor receptors, and cell cycle mediators to promote growth and replication. In many cases, the translocations are not simple reciprocal events but involve complex rearrangements with changes in copy numbers of important gene drivers, oncogenes, and tumor suppressor genes. Additionally, complex genomic rearrangements can lead to overexpression/underexpression of sets of genes based on their proximity to topologically associating transcriptional domains [<a href="#rid27">27</a>]. (See <a class="local">'Mechanisms resulting in complex structural variants'</a> below.)</p><p>The percentage of cases displaying IgH translocations increases as the disease progresses from MGUS to MM. IgH translocations are found in nearly 50 percent of patients with MGUS or smoldering MM, 55 to 73 percent of those with MM, 85 percent of plasma cell leukemias, and &gt;90 percent of in vitro human myeloma cell lines [<a href="#rid28">28,29</a>]. This may reflect the fact that certain types of IgH translocated MGUS and MM (eg, t(14;16), t(14;20)) may be more aggressive than the hyperdiploid type of MGUS.</p><p class="headingAnchor" id="H8"><span class="h3">Trisomies/hyperdiploidy</span><span class="headingEndMark"> — </span>The majority of MGUS cases that do not have translocations involving IgH demonstrate genetic instability manifested by the gain of chromosomes (trisomies) [<a href="#rid23">23,30-35</a>]. This subset of MGUS is referred to as "IgH nontranslocated MGUS" or "hyperdiploid MGUS."</p><p>Hyperdiploid MGUS and MM typically demonstrate trisomies of one or more odd numbered chromosomes, with the exception of chromosomes 1, 13, and 21. These trisomies are not acquired from a single event, but are rather a result of a consecutive accumulation of multiple genetic events [<a href="#rid36">36</a>]. Trisomies can result in the overexpression of genes located on the affected chromosomes, and these genes may promote growth and replication leading to the MGUS clone.</p><p class="headingAnchor" id="H2354215343"><span class="h3">Other genomic copy number variations</span><span class="headingEndMark"> — </span>Complex genomic rearrangements in MGUS often lead to other losses and/or gains of whole chromosomes and smaller chromosome regions, such as loss of chromosome 13 and gain of the whole arm of chromosome 1q [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1664732991"><span class="h2">Mechanisms resulting in complex structural variants</span><span class="headingEndMark"> — </span>The genomic complexity of MM is similar to that of lymphomas (less complex than solid tumors, more complex than leukemias). Complex structural variants are primarily caused by:</p><p class="bulletIndent1"><span class="glyph">●</span>Chromothripsis – Shattering of whole chromosomes with subsequent random reassembly and oscillating copy number changes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chromoplexy – Multiple simultaneous double-stranded DNA breaks with incorrect rejoining, resulting in regional DNA copy number losses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Templated insertions – Similar to chromoplexy but with insertions of copied DNA material into the new genomic region, resulting in DNA copy number gains.</p><p></p><p class="headingAnchor" id="H730735872"><span class="h2">Aberrant cyclin D expression dysregulates cell cycle progression</span><span class="headingEndMark"> — </span>Cyclin D genes appear to be universally dysregulated in early stages of MM development, promoting cell cycle progression and tumor proliferation [<a href="#rid37">37,38</a>]. Aberrant cyclin D expression can occur through several mechanisms, including translocations involving <em>CCND1</em> (11q23), <em>CCND2</em> (12p13), and <em>CCND3</em> (6p21) genes, MAF-induced upregulation of <em>CCND2</em> transcription, and point mutations in the <em>CCND1</em> gene [<a href="#rid39">39,40</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Abnormal response to antigenic stimulation</span><span class="headingEndMark"> — </span>The cytogenetic abnormalities described above are thought to be the result of an abnormal, sustained response to antigenic stimulation.</p><p>The nature of the antigenic stimulus is unknown and likely differs between cases. As an example, one study found that a high percentage of patients (17 of 20 patients) with Gaucher disease-associated MM had monoclonal immunoglobulins with reactivity against the lysolipid LGL-1 [<a href="#rid41">41</a>]. In contrast, monoclonal immunoglobulins with reactivity against LGL-1 or another lysolipid, lysophosphatidylcholine (LPC), were found in only a minority of patients with sporadic MM (22 of 66 patients). Polyclonal serum free light chain elevation is associated with an increased risk of MGUS, providing further support for prolonged immune stimulation as a contributing factor to the development of plasma cell neoplasms [<a href="#rid42">42</a>].</p><p>The reason why an antigenic stimulus produces an abnormal, sustained, proliferative signal for plasma cells is unclear. One likely contributing factor is re-entry/persistence of a plasma cell precursor in germinal centers and the resulting exposure to the mutagenic effect of activation-induced cytidine deaminase (AID). During normal germinal center reactions, AID mediates somatic hypermutation and class switching. Typical signatures of early/clonal (as opposed to late/subclonal) AID mutational activity are seen in the vast majority of myelomas [<a href="#rid43">43</a>]. Based on the frequency of age-related mutations in symptomatic MM, it appears that the initial cytogenetic events causing MGUS occur in early adulthood [<a href="#rid44">44</a>]. </p><p class="headingAnchor" id="H3245442396"><span class="h2">Homing of premalignant plasma cell in bone marrow</span><span class="headingEndMark"> — </span>Having acquired primary cytogenetic abnormalities, premalignant plasma cells travel to the bone marrow, a homing mechanism which is shared with their normal counterparts. The survival and growth of these cells depends on complex interactions with the bone marrow microenvironment. (See <a class="local">'Bone marrow microenvironment'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h1">PROGRESSION OF MGUS TO MM</span><span class="headingEndMark"> — </span>The main driver for progression of monoclonal gammopathy of undetermined significance (MGUS) to MM is accumulation of additional genetic changes, both structural variants and single nucleotide variants. These changes confer proliferative and/or survival benefit to the plasma cell clone in the context of bone marrow microenvironment.</p><p>There are two important concepts to keep in mind when thinking about the progression of MGUS to MM: </p><p class="bulletIndent1"><span class="glyph">●</span>Although there is a sequential accumulation of genetic changes, the risk of progressing from MGUS to MM is remarkably constant over time in an individual (1 percent per year), suggesting that a single or a small number of "catastrophic" events is likely responsible. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical classification of MGUS, smoldering MM, and MM is based on a tumor burden assessment using widely available technologies, rather than on the biology of the disease. In contrast, whole-genome sequencing suggests that there are two different types of MM precursors (stable versus progressive) that may be identified based on the presence of specific genetic changes, regardless of the percentage of plasma cells in the bone marrow [<a href="#rid45">45</a>]. Further studies of these stable versus progressive precursors may help us better understand progression.</p><p></p><p class="headingAnchor" id="H3089555852"><span class="h2">Mechanism of secondary changes</span><span class="headingEndMark"> — </span>The same large genomic events responsible for clone initiation (chromothripsis, chromoplexy, templated insertions) can occur at the MGUS to MM transition. Multiple single nucleotide mutational signatures are observed, the most important of which appears to be the mutagenic activity of APOBEC cytidine deaminase [<a href="#rid39">39,46</a>]. In addition, epigenetic changes such as DNA methylation and histone modifications contribute to dysregulation of gene expression [<a href="#rid47">47,48</a>].</p><p class="headingAnchor" id="H1748149155"><span class="h2">Drivers of progression from MGUS to MM</span><span class="headingEndMark"> — </span>Genetic changes driving the progression from MGUS to MM dysregulate intracellular pathways involved in cell proliferation, survival, and DNA repair. The most important genes/pathways for progression include:</p><p class="bulletIndent1"><span class="glyph">●</span>MYC activation, mostly by structural rearrangements [<a href="#rid49">49</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><em>TP53</em> deletion, both by 17p deletion and point mutations [<a href="#rid39">39</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Activation of RAS/MAPK pathway by point mutations in <em>NRAS</em>, <em>KRAS</em>, <em>BRAF</em>, or genes encoding downstream signaling molecules [<a href="#rid39">39</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Activation of NFkB pathway by mutations in <em>TRAF3</em>, <em>CYLD</em>, <em>NIK</em>, or other genes [<a href="#rid39">39</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Dysregulation of apoptosis, including MCL1 overexpression [<a href="#rid39">39</a>]</p><p></p><p>The accumulation of secondary mutations is not random; the type and frequency is correlated with primary genetic changes [<a href="#rid22">22</a>]. As examples [<a href="#rid22">22,40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperdiploid myelomas are enriched in <em>NRAS</em> mutations</p><p class="bulletIndent1"><span class="glyph">●</span>t(11;14) is associated with <em>KRAS</em>, <em>IRF4</em>, and <em>CCND1</em> mutations</p><p class="bulletIndent1"><span class="glyph">●</span>t(4;14) often has mutations in <em>FGFR3</em>, <em>DIS3</em>, and <em>PRKD2  </em></p><p></p><p>During this process, a number of different branching subclones are formed, with high temporal and spatial heterogeneity [<a href="#rid50">50,51</a>]. Additional subclones frequently emerge post-therapy, at disease relapse. One study showed that incorporating genomic alterations from high-sensitivity studies can improve clinical stratification and potential management of newly diagnosed MM [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Bone marrow microenvironment</span><span class="headingEndMark"> — </span>The bone microenvironment is a complex 3D structure composed of: </p><p class="bulletIndent1"><span class="glyph">●</span>Various cells (mesenchymal stem cells, osteoclasts, osteoblasts, adipose cells, hematopoietic cells, immune cells)</p><p class="bulletIndent1"><span class="glyph">●</span>Extracellular matrix (collagens, fibronectin, laminin, thrombospondin, proteoglycans)</p><p class="bulletIndent1"><span class="glyph">●</span>Soluble factors (growth factors, cytokines, chemokines) </p><p></p><p>Numerous changes in the bone marrow microenvironment support the survival of the abnormal plasma cell clone in MGUS and enable the progression of MGUS to MM. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Induction of angiogenesis [<a href="#rid53">53,54</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Immune dysregulation [<a href="#rid55">55-59</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Paracrine loops involving cytokines such as interleukin (IL)-6 and vascular endothelial growth factor (VEGF) [<a href="#rid60">60</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Modulation of tumor growth by bone marrow stromal cell [<a href="#rid61">61,62</a>]</p><p></p><p class="headingAnchor" id="H22"><span class="h2">Pathobiology of end organ damage</span><span class="headingEndMark"> — </span>Once the clonal plasma cell population is created and progresses to MM, patients develop symptoms (eg, hypercalcemia, lytic bone lesions, renal dysfunction, and anemia) related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Osteolytic bone lesions</span><span class="headingEndMark"> — </span>Osteolytic bone lesions are the hallmark of MM. Although there are some data suggesting abnormalities in bone metabolism in MGUS, the presence of osteolytic bone lesions signals the onset of active malignancy. The pathogenesis of lytic bone lesions characteristic of MM is thought to be mediated by an imbalance between the activity of osteoclasts and osteoblasts. This imbalance is caused both by enhanced osteoclastic activity as well as (in contrast to other malignancies) a marked suppression of osteoblastic activity. As a result, MM bone lesions tend to be purely osteolytic and better visualized on plain radiographs compared with other bone metastases from solid tumors that tend to have an osteoblastic component and are better visualized on radionucleotide bone scans.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased osteolytic activity</strong> – Increased osteolytic activity is mediated by an increase in RANKL (receptor activator of nuclear factor kappa-B ligand) expression by osteoblasts (and possibly plasma cells) accompanied by a reduction in the level of its decoy receptor, osteoprotegerin (OPG) [<a href="#rid63">63,64</a>]. This leads to an increase in RANKL/OPG ratio, which causes osteoclast activation and bone resorption. Increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha, CCL3), IL-3, and IL-6 produced by marrow stromal cells also contribute to the overactivity of osteoclasts. Finally, there is increased expression of stromal derived factor 1 alpha (SDF-1alpha) by stromal cells and myeloma cells [<a href="#rid65">65</a>]. SDF-1alpha causes osteoclast activation by binding to CXCR4 on osteoclast precursors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoblast suppression</strong> – Active suppression of osteoblasts is most likely related to increased levels of IL-3, IL-7, and dickkopf 1 (DKK1), which inhibit osteoblast differentiation in MM [<a href="#rid66">66</a>]. MM cells express DKK1, an inhibitor of Wnt signaling, and increased expression of DKK1 by these cells has been associated with presence of focal bone lesions in MM [<a href="#rid66">66</a>]. Increased IL-3 and IL-7 levels may also play a role.</p><p></p><p class="headingAnchor" id="H24"><span class="h3">Hypercalcemia</span><span class="headingEndMark"> — </span>Hypercalcemia appears to be a product of osteoclast activating factors such as lymphotoxin, IL-6, hepatocyte growth factor, and RANKL. (See  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia", section on 'Malignancy'</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Kidney impairment</span><span class="headingEndMark"> — </span>Kidney involvement in MM is usually the result of monoclonal immunoglobulin light chains. However, in rare occasions, monoclonal heavy chains or the entire immunoglobulins may be involved. Non-monoclonal protein-related kidney injury may also occur. (See  <a class="medical medical_review" href="/z/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation"</a>.)</p><p class="headingAnchor" id="H26"><span class="h3">Anemia</span><span class="headingEndMark"> — </span>Involvement of the bone marrow in MM can result in anemia thought to be due to both the replacement of normal hematopoietic tissue by tumor (myelophthisis) and by the disruption of the bone marrow microenvironment. (See  <a class="medical medical_review" href="/z/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer", section on 'Bone marrow infiltration'</a>.)</p><p>The relatively common occurrence of anemia in the setting of limited bone marrow infiltration suggests that MM-associated anemia is not entirely due to bone marrow replacement by malignant cells. Importantly, the bone marrow of patients with MM contains lower than normal numbers of hematopoietic stem and progenitor cells [<a href="#rid67">67</a>]. This reduction in hematopoietic precursors appears to be at least partially due to changes in the bone marrow microenvironment. Elimination of myeloma cells and restoration of the normal bone marrow environment may result in repopulation with these precursors and reversal of the anemia.</p><p>Other frequent causes of anemia in patients with MM include relative erythropoietin deficiency (in part due to kidney damage) and therapeutic (cytotoxic) drugs.</p><p class="headingAnchor" id="H954421"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/688.html" rel="external">"Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/690.html" rel="external">"Patient education: Multiple myeloma treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scope of disease</strong> – Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10 percent of all hematologic malignancies and evolves from an asymptomatic premalignant stage of clonal plasma cell proliferation termed monoclonal gammopathy of undetermined significance (MGUS). (See <a class="local">'Overview of pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell of origin</strong> – Most cases of MM arise from the malignant transformation of post-germinal center plasma cells, whereas rare instances of IgM MM arise from a pre-germinal center plasma cell. (See <a class="local">'Cell of origin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Step-wise evolution</strong> – The pathogenesis of MM is complex and poorly understood. However, a two-step model of progression best describes clinical presentation  (<a class="graphic graphic_figure graphicRef78232" href="/z/d/graphic/78232.html" rel="external">figure 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Establishment of MGUS</strong> – Primary cytogenetic abnormalities play a major role in the establishment of a limited stage of clonal proliferation, clinically recognized as MGUS. These include immunoglobulin heavy chain (IgH) translocations, hyperdiploidy, and copy number variations, including complex structural changes. (See <a class="local">'Establishment of MGUS'</a> above.)</p><p></p><p class="bulletIndent2">These abnormalities may be the product of an abnormal, sustained response to antigenic stimulation, and errors that occur at the time of immunoglobulin switch recombination. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progression of MGUS to MM</strong> – A single or a small number of additional (secondary) genetic events results in progression to MM. Interaction of plasma cells with bone marrow microenvironment is an important part of disease pathogenesis. (See <a class="local">'Progression of MGUS to MM'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>End-organ damage</strong> – Symptoms (eg, hypercalcemia, lytic bone lesions, kidney impairment, and anemia) are related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains. (See <a class="local">'Pathobiology of end organ damage'</a> above.)</p><p></p><p class="headingAnchor" id="H338588583"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges extensive contributions of Robert A Kyle, MD to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68:190.</a></li><li><a class="nounderline abstract_t">Bazarbachi AH, Avet-Loiseau H, Szalat R, et al. IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood 2021; 138:1980.</a></li><li><a class="nounderline abstract_t">Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 1993; 178:1091.</a></li><li><a class="nounderline abstract_t">Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103:2332.</a></li><li><a class="nounderline abstract_t">Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 1992; 6:297.</a></li><li><a class="nounderline abstract_t">Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355:248.</a></li><li><a class="nounderline abstract_t">Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113:5412.</a></li><li><a class="nounderline abstract_t">Murray D, Kumar SK, Kyle RA, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J 2019; 9:102.</a></li><li><a class="nounderline abstract_t">Ichimaru M, Ishimaru T, Mikami M, Matsunaga M. Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: relationship to radiation dose absorbed by marrow. J Natl Cancer Inst 1982; 69:323.</a></li><li><a class="nounderline abstract_t">Iwanaga M, Tagawa M, Tsukasaki K, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood 2009; 113:1639.</a></li><li><a class="nounderline abstract_t">Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994; 137:S68.</a></li><li><a class="nounderline abstract_t">LEWIS EB. LEUKEMIA, MULTIPLE MYELOMA, AND APLASTIC ANEMIA IN AMERICAN RADIOLOGISTS. Science 1963; 142:1492.</a></li><li><a class="nounderline abstract_t">Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992; 6:225.</a></li><li><a class="nounderline abstract_t">Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007; 20:637.</a></li><li><a class="nounderline abstract_t">Zandecki M, Laï JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996; 94:217.</a></li><li><a class="nounderline abstract_t">Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 2001; 112:167.</a></li><li><a class="nounderline abstract_t">Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99:1745.</a></li><li><a class="nounderline abstract_t">Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000; 96:808.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27:4585.</a></li><li><a class="nounderline abstract_t">Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23:2210.</a></li><li><a class="nounderline abstract_t">Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 2018; 132:587.</a></li><li><a class="nounderline abstract_t">Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64:1546.</a></li><li><a class="nounderline abstract_t">Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175.</a></li><li><a class="nounderline abstract_t">Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001; 20:5611.</a></li><li><a class="nounderline abstract_t">Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100:1417.</a></li><li><a class="nounderline abstract_t">Spielmann M, Lupiáñez DG, Mundlos S. Structural variation in the 3D genome. Nat Rev Genet 2018; 19:453.</a></li><li><a class="nounderline abstract_t">Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101:4569.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99:2185.</a></li><li><a class="nounderline abstract_t">Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995; 86:3915.</a></li><li><a class="nounderline abstract_t">Fonseca R, Aguayo P, Ahmann GJ, et al. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes. Blood 1999; 94(Suppl1):663a.</a></li><li><a class="nounderline abstract_t">Rajkumar SV. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program 2005; :340.</a></li><li><a class="nounderline abstract_t">Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005; 106:2156.</a></li><li><a class="nounderline abstract_t">Magrangeas F, Lodé L, Wuilleme S, et al. Genetic heterogeneity in multiple myeloma. Leukemia 2005; 19:191.</a></li><li><a class="nounderline abstract_t">Kaufmann H, Ackermann J, Baldia C, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18:1879.</a></li><li><a class="nounderline abstract_t">Maura F, Bolli N, Angelopoulos N, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun 2019; 10:3835.</a></li><li><a class="nounderline abstract_t">Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106:296.</a></li><li><a class="nounderline abstract_t">Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001; 98:217.</a></li><li><a class="nounderline abstract_t">Maura F, Petljak M, Lionetti M, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia 2018; 32:1044.</a></li><li><a class="nounderline abstract_t">Walker BA, Boyle EM, Wardell CP, et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol 2015; 33:3911.</a></li><li><a class="nounderline abstract_t">Nair S, Branagan AR, Liu J, et al. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 2016; 374:555.</a></li><li><a class="nounderline abstract_t">Kumar S, Larson DR, Dispenzieri A, et al. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. Blood Cancer J 2019; 9:49.</a></li><li><a class="nounderline abstract_t">Maura F, Rustad EH, Yellapantula V, et al. Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia 2020; 34:1476.</a></li><li><a class="nounderline abstract_t">Rustad EH, Yellapantula V, Leongamornlert D, et al. Timing the initiation of multiple myeloma. Nat Commun 2020; 11:1917.</a></li><li><a class="nounderline abstract_t">Oben B, Froyen G, Maclachlan KH, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun 2021; 12:1861.</a></li><li><a class="nounderline abstract_t">Walker BA, Wardell CP, Murison A, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun 2015; 6:6997.</a></li><li><a class="nounderline abstract_t">De Smedt E, Lui H, Maes K, et al. The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response. Front Oncol 2018; 8:566.</a></li><li><a class="nounderline abstract_t">Pawlyn C, Kaiser MF, Heuck C, et al. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin Cancer Res 2016; 22:5783.</a></li><li><a class="nounderline abstract_t">Misund K, Keane N, Stein CK, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia 2020; 34:322.</a></li><li><a class="nounderline abstract_t">Rasche L, Chavan SS, Stephens OW, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 2017; 8:268.</a></li><li><a class="nounderline abstract_t">Diamond B, Yellapantula V, Rustad EH, et al. Positive selection as the unifying force for clonal evolution in multiple myeloma. Leukemia 2021; 35:1511.</a></li><li><a class="nounderline abstract_t">Maura F, Rajanna AR, Ziccheddu B, et al. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol 2024; :JCO2301277.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8:2210.</a></li><li><a class="nounderline abstract_t">Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003; 101:1715.</a></li><li><a class="nounderline abstract_t">Galea HR, Cogné M. GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model. Clin Exp Immunol 2002; 129:247.</a></li><li><a class="nounderline abstract_t">Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100:230.</a></li><li><a class="nounderline abstract_t">Noonan K, Marchionni L, Anderson J, et al. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116:3554.</a></li><li><a class="nounderline abstract_t">Tamura H, Ishibashi M, Yamashita T, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013; 27:464.</a></li><li><a class="nounderline abstract_t">Paiva B, Azpilikueta A, Puig N, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia 2015; 29:2110.</a></li><li><a class="nounderline abstract_t">Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88:176.</a></li><li><a class="nounderline abstract_t">Roccaro AM, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013; 123:1542.</a></li><li><a class="nounderline abstract_t">Reagan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res 2012; 18:342.</a></li><li><a class="nounderline abstract_t">Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002; 17:1921.</a></li><li><a class="nounderline abstract_t">Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655.</a></li><li><a class="nounderline abstract_t">Sezer O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 2009; 14:276.</a></li><li><a class="nounderline abstract_t">Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483.</a></li><li><a class="nounderline abstract_t">Bruns I, Cadeddu RP, Brueckmann I, et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood 2012; 120:2620.</a></li></ol></div><div id="topicVersionRevision">Topic 6660 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172311" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34792571" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8350048" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630803" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characterization of clonogenic multiple myeloma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1533857" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675068" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : New insights into role of microenvironment in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179464" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31836698" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6955540" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: relationship to radiation dose absorbed by marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849487" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127953" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14077037" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : LEUKEMIA, MULTIPLE MYELOMA, AND APLASTIC ANEMIA IN AMERICAN RADIOLOGISTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1582971" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The epidemiology of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070711" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Epidemiology of the plasma-cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759879" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Multiple myeloma: almost all patients are cytogenetically abnormal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167798" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11861292" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910891" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687334" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prognostic significance of copy-number alterations in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19798094" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29884741" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14989251" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Genetics and cytogenetics of multiple myeloma: a workshop report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990854" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Multiple myeloma: evolving genetic events and host interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11607813" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chromosome translocations in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12149226" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genomic abnormalities in monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29692413" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Structural variation in the 3D genome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576322" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical and biologic implications of recurrent genomic aberrations in myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877296" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579361" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304401" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920009" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15538406" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Genetic heterogeneity in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385925" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31444325" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Genomic landscape and chronological reconstruction of driver events in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755896" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11418483" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29209044" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282654" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26863356" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31101803" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31836853" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317634" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Timing the initiation of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33767199" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25904160" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30619733" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27235425" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31439946" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : MYC dysregulation in the progression of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814763" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33483619" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Positive selection as the unifying force for clonal evolution in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38194610" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genomic Classification and Individualized Prognosis in Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114422" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393501" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prognostic value of angiogenesis in solitary bone plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165080" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12070032" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664052" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22828443" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25778100" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12604407" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23454749" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22065077" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12412796" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Role of the bone marrow microenvironment in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084698" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mechanisms of bone metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19286761" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Myeloma bone disease: recent advances in biology, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14695408" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517906" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
